Microangiopathy in Diabetes

NCT ID: NCT07145567

Last Updated: 2025-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will employ investigational devices to evaluate microvascular function and correlate it to degree of microangiopathy in persons with diabetes type 1 and healthy controls.

The investigational device, TCI P4, is a novel, contactless, non-invasive, non-CE marked, class IIa Spatial Frequency Domain Imaging (SFDI) system. The device utilizes an LED light projector to cast patterned, multi-wavelength light onto the skin while multiple cameras capture narrow-band reflections. This method yields two-dimensional data on skin structure and molecular composition (including hemoglobin, oxygen, and water). Established comparators such as laser speckle contrast imaging (LSCI) and the EPOS system are employed to benchmark device performance and validate measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microangiopathy Microvascular Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe diabetic microangiopathy

Severe micro-angiopathy defined as proliferative retinopathy, macroalbuminuria, and kidney failure with at least CKD-class 3B and severe neuropathy with or without foot ulcers. Aged 18-60 years old.

No interventions assigned to this group

Moderate diabetic microangiopathy

Moderate non-proliferative retinopathy or proliferative retinopathy, macroalbuminuria or kidney failure defined as estimated glomerular filtration rate \<60 mL/min/1.73 m2 body surface, and manifest neuropathy. Aged 18-45 years old.

No interventions assigned to this group

Mild diabetic microangiopathy

Mild-moderate non-proliferative retinopathy and/or microalbuminuria and/or early signs of neuropathy. Aged 18-45 years old.

No interventions assigned to this group

No diabetic microangiopathy

No microangiopathic complications, except for simplex or background retinopathy, which is an early and reversible state. Aged 18-45 years old.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetes mellitus type 1.

Exclusion Criteria

* Patients unable to understand patient information due to cognitive impairment.
* Patients unable to understand patient information due to language barriers.
* Ongoing acute infection disease or inflammatory condition.
* Pregnant or breast-feeding women.
* Patients with damaged and/or scarred tissue in the areas of interest for the investigational or comparator devices.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neko Health AB

UNKNOWN

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Tehrani

Principal investigator, Medical doctor, Specialist in internal medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Danderyd University Hospital

Danderyd, Stockholm County, Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sara Tehrani, Medical Doctor

Role: CONTACT

+46 08 123 550 00

Jacob Widaeus, Medical Doctor

Role: CONTACT

+46 08 123 596 01

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sara Tehrani, Medical Doctor

Role: primary

+460812355000

Jacob Widaeus, Medical Doctor

Role: backup

+460812359601

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-02232-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SweMaMi DMI, Microbiome
NCT04346524 UNKNOWN
Type 1 Diabetes Autonomic and Vascular Function
NCT06786546 ENROLLING_BY_INVITATION